OncoNano Medicine is a biotech company that develops pH-activated compounds that digitalize and exploit the variability of pH in disease.
Onconano Medicine has raised $18.4M in total funding. The most recent round was Series B. The last funding was announced in October 2021.
Onconano Medicine's investors include Cancer Prevention and Research Institute of Texas, Salem Partners, Advantech Capital, Adam Okun.
Onconano Medicine is headquartered in Dallas, United States.
OncoNano Medicine is a biotech company that develops pH-activated compounds that digitalize and exploit the variability of pH in disease.
Onconano Medicine is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Onconano Medicine — Funding & Investors." VCBacked, October 25, 2021, https://www.vcbacked.co/company/onconano-medicine. Accessed August 14, 2026.
VCBacked. (2021). Onconano Medicine — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/onconano-medicine
{{cite web |title=Onconano Medicine — Funding & Investors |url=https://www.vcbacked.co/company/onconano-medicine |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated